TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better

Research output: Contribution to journalArticlepeer-review

Abstract

IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell-mediated control.See related article by Chauvin et al., p. 5520.

Original languageEnglish
Pages (from-to)5274-5275
Number of pages2
JournalClin. Cancer Res.
Volume26
Issue number20
DOIs
Publication statusPublished - Oct 15 2020

Fingerprint Dive into the research topics of 'TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better'. Together they form a unique fingerprint.

Cite this